Document is current
Any future updates will be listed below
-
Authors
Coulombe, Benoit https://orcid.org/0000-0003-1702-0692
Durcan, Thomas M.
Bernard, Geneviève
Moursli, Asmae
Poitras, Christian
Faubert, Denis
Pinard, Maxime
-
Funding
Funding for this research was provided by:
Mcgill Healthy brains for Healthy Lives initiative
Ministère de l'économie, de l'innovation et de l'énergie
Private investor WinnerMax Capital Inc.
Canadian Institutes of Health Research (New investigator salary award, PJT-169095)
Fondation Leucodystrophie
Yaya foundation for 4H leukodystrophy
Fondation Les amis d'Élliot
Fondation Le Tout pour Loo
Fondation du Grand défi Pierre Lavoie
research institute of the mcgill university health centre
Leuco-action
Fondation de l'Hôpital de Montréal pour enfants
Fonds de Recherche du Québec - Santé (Clinical Research Scholar Junior 1, Clinical Research Scholar Senior)
CQDM Quantum Leaps program
Alain and Sandra Bouchard Foundation
Sebastien and Ghislaine Van Berkom foundation
Medicament Québec
Chamandy Foundation
Djavad Mowafaghian Foundation
Bell-bombardier chair of excellentce at the IRCM
- License Information
-
More Information
Article History
Received: 31 January 2024
Accepted: 15 March 2024
First Online: 11 April 2024
Declarations
:
: Not applicable.
: Not applicable.
: Dr. Bernard is/was a consultant for Calico (2023-present), Orchard Therapeutics (2023-present), Passage Bio Inc (2020–2022) and Ionis (2019). She is/was a site investigator for the Alexander’s disease trial of Ionis (2021-present), Metachromatic leukodystrophy of Shire/Takeda (2020–2021), Krabbe (2021–2023) and GM1 gene therapy trials of Passage Bio (2021-present), GM1 natural history study from the University of Pennsylvania sponsored by Passage Bio (2021-present) and Adrenoleukodystrophy/Hematopoietic stem cell transplantation natural history study of Bluebird Bio (2019), a site sub-investigator for the MPS II gene therapy trial of Regenxbio (2021-present) and the MPS II clinical trial of Denali (2022-present). She has received an unrestricted educational grant from Takeda (2021–2022).
